Acquiring Company
Veracyte
Acquired Company
Convergent Genomics
South San FranciscoDelawareBiotechnologyHealth CareArtificial IntelligenceGeneticsHealth DiagnosticsBiotechnologyHealth CareGeneticsHealth DiagnosticsDescription
On September 10, 2026, Veracyte, Inc. entered into a Merger Agreement with Convergent Genomics Inc. On September 14, 2026, Convergent was merged into Veracyte's wholly-owned subsidiary, Merger Sub, ceasing to exist separately. Convergent will continue as a wholly owned subsidiary of Veracyte. This acquisition aims to enhance Veracyte's genomic diagnostics portfolio.
Don't miss Veracyte's next move
Get an email the moment Veracyte makes an acquisition, hires an exec, or expands, usually minutes after it happens.
One email per event. Unsubscribe anytime.
Related People
M&A Insights
Based on deal dataFrequently asked
Who acquired Convergent Genomics?
Convergent Genomics was acquired by Veracyte, based in South San Francisco. The deal was reported on September 14, 2026. Veracyte, Inc. is a leading cancer diagnostics company specializing in transforming cancer care through high-performing tests. Veracyte is publicly traded (VCYT) and operates in Biotechnology.
When did Veracyte acquire Convergent Genomics?
Veracyte's acquisition of Convergent Genomics was reported on September 14, 2026. On September 10, 2026, Veracyte, Inc. entered into a Merger Agreement with Convergent Genomics Inc. On September 14, 2026, Convergent was merged into Veracyte's wholly-owned subsidiary, Merger Sub, ceasing to exist separately. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Convergent Genomics do?
Convergent Genomics Inc. is a biotechnology company specializing in genomic diagnostics, particularly for bladder cancer. Their focus is on developing tests that provide actionable insights to clinicians and patients. It is privately held, operating in Biotechnology, and is based in Delaware.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.
5 screens from a live account. No signup.